source
- FDA approves Rasonque, first therapy targeting genetic cause of advanced pancreatic cancerThe U.S. Food and Drug Administration has granted approval to Rasonque, a drug from Revolution Medicines, for patients with advanced pancreatic cancer. The medicine, whose generic name is daraxonra…
- Profit motive highlighted as key to advancing women’s health research and boosting economic productivityExperts say that turning to the profit motive could spur investment in under‑funded women’s health areas such as endometriosis, osteoporosis and autoimmune disorders. They note a long history of r…